Jobs
-
Inhalation CDMO Bespak recently announced that it will close its site in Research Triangle Park, NC, USA by the end of the first quarter of 2025. Bespak spun out from Recipharm earlier this year with… Read more . . .
-
CRO OzUK has announced the availability of a new GLP pilot plant designed for pilot and feasibility studies of both solution and suspension MDIs filled with low global warming potential (LGWP) propellants. OzUK announced plans… Read more . . .
-
Tiziana Life Sciences announced that a preclinical study of its intranasal foralumab in combination with semaglutide (Ozempic / Wegovy) demonstrated synergistic effects in a mouse model of obesity, improving liver function and reducing inflammation more… Read more . . .
-
MannKind Corporation has announced that data from a recently completed Phase 1 study of MNKD-201 nintedanib DPI support continued development of the inhaler for the treatment of idiopathic pulmonary fibrosis (IPF). MannKind had announced plans for… Read more . . .
-
Kither Biotech has announced the initiation of a Phase 1 trial of its KIT2014, an inhaled peptide that the company is developing as a CFTR enhancer for use as an add-on with CFTR modulators for… Read more . . .
-
Satsuma Pharmaceuticals announced that it has resubmitted its NDA for STS101 intranasal dry powder dihydroergotamine for the acute treatment of migraine with or without aura. The company initially submitted the NDA in March 2023 even though the… Read more . . .
-
Intranasal hydrogel maker Polyrizon announced that it has closed a $4.2 million IPO, with a possibility of the total rising to $4.82 million if Aegis Capital exercises an option to purchase additional shares. Polyrizon said… Read more . . .
-
Sensory Cloud has announced the publication of an article in ERJ Open Research presenting data from a study of its SC001 intranasal alkaline hypertonic divalent salt in patients with refractory chronic cough (RCC). The company… Read more . . .
-
AuraVax Therapeutics announced that the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a preclinical research contract to support evaluation of AuraVax’s NanoSTING-002 mucosal adjuvant… Read more . . .
-
French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company’s pipeline includes nasal vaccines against zoonotic diseases… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland